Renal Cell Carcinoma

RENAL CELL CARCINOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COSMIC-313: Triplet Prolongs PFS vs Doublet in Renal Cell Carcinoma

The PFS benefit was driven primarily by patients with intermediate-risk disease.
Adjuvant Nivolumab-Ipilimumab Failed to Improve DFS in Renal Cell Carcinoma

Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
Previous Cannabis Use Linked to Lower Risk of Some Genitourinary Cancers

A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Cabozantinib Demonstrates Activity in Advanced Translocation Renal Cell Carcinoma

Cabozantinib can produce durable responses in patients with advanced MiT family translocation renal cell carcinoma, a new study suggests.
Normonatremia Tied to Outcomes in Metastatic Renal Cell Carcinoma

Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.

RENAL CELL CARCINOMA NEWS

Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates

March 21, 2023

Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC

March 17, 2023

nephrectomy-kidney-surgery

Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC

March 16, 2023

Kidneys

Benefits Persist for Lenvatinib Plus Pembrolizumab in Renal Cell Cancer

March 15, 2023

lymph nodes

RCC Stratification System May Need to Be Refined, Data Suggest

March 14, 2023

Next post in Renal Cell Carcinoma

Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC